GYNECOLOGIC CANCERS

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

Discover groundbreaking advancements in gynecologic oncology, offering new hope for patients with challenging cancers through innovative therapies and clinical trials.

AstraZeneca and Daiichi Sankyo launch a pivotal trial to assess T-DXd as a potential adjuvant therapy for HER2-expressing endometrial cancer.

JSKN003, a novel HER2-targeting ADC, shows promising efficacy in treating platinum-resistant ovarian cancer, earning FDA breakthrough therapy designation.

A recent study reveals high rates of metastatic recurrence in adolescent and young adult cancer patients, emphasizing the need for tailored survivorship care.

Ipatasertib shows promising efficacy in heavily pretreated patients with AKT1E17K mutations, highlighting its potential in diverse tumor types.

New research reveals that high CD8-positive T-cell infiltration worsens outcomes for ovarian cancer patients treated with bevacizumab, challenging existing prognostic models.

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

New findings reveal that adding sapanisertib to weekly paclitaxel significantly improves progression-free survival in advanced ovarian cancer patients.

Camrelizumab and famitinib significantly enhance progression-free survival in recurrent cervical cancer compared to traditional chemotherapy, offering a promising new treatment option.

Early-stage cervical cancer treatment significantly boosts survival rates in older patients, highlighting the need for tailored care strategies.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.

IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.

New trial results reveal sacituzumab govitecan shows significant antitumor activity in recurrent cervical cancer, especially in heavily pretreated patients.

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing patient care options.

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a groundbreaking cancer therapy.

A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a phase 1/2 trial.